Open Access

Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine

  • Authors:
    • Romana Mikyšková
    • Marie Indrová
    • Jana Šímová
    • Jana Bieblová
    • Jan Bubeník
    • Milan Reiniš
  • View Affiliations

  • Published online on: March 18, 2011     https://doi.org/10.3892/or.2011.1221
  • Pages: 1683-1689
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Genetically modified tumour cells producing cytokines such as interleukin 12 (IL-12) are potent activators of the antitumour immune responses and represent a promising therapeutic modality when combined with chemotherapy. The objective of this study was to examine whether IL-12-producing cellular vaccines can augment chemotherapy of human papilloma virus (HPV) 16-associated murine tumours with the cytostatic agent gemcitabine (GEM). We found that peritumoral administration of IL-12-producing tumour vaccines enhanced the effect of cytoreductive therapy with GEM both in non-metastasizing murine carcinoma TC-1 and in metastasizing murine carcinoma MK16. The percentage of mice with MK16 metastases and the number of lung metastatic nodules was substantially decreased. In another clinically relevant setting, surgical minimal residual tumour disease, the administration of IL-12-producing tumour vaccine and GEM after the MK16 tumour surgery reduced the percentage of mice with tumour recurrences; similarly, the percentage of metastasis-bearing mice and the number of metastatic nodules was decreased. Tumour inhibitory effects exerted by GEM plus IL-12 were associated with high production of interferon-γ (IFNγ) by splenocytes. Our results suggest that the IL-12-producing vaccine can enhance the effect of GEM chemotherapy in some HPV16-associated murine tumour models.

Related Articles

Journal Cover

June 2011
Volume 25 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mikyšková R, Indrová M, Šímová J, Bieblová J, Bubeník J and Reiniš M: Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine. Oncol Rep 25: 1683-1689, 2011.
APA
Mikyšková, R., Indrová, M., Šímová, J., Bieblová, J., Bubeník, J., & Reiniš, M. (2011). Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine. Oncology Reports, 25, 1683-1689. https://doi.org/10.3892/or.2011.1221
MLA
Mikyšková, R., Indrová, M., Šímová, J., Bieblová, J., Bubeník, J., Reiniš, M."Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine". Oncology Reports 25.6 (2011): 1683-1689.
Chicago
Mikyšková, R., Indrová, M., Šímová, J., Bieblová, J., Bubeník, J., Reiniš, M."Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine". Oncology Reports 25, no. 6 (2011): 1683-1689. https://doi.org/10.3892/or.2011.1221